Overview

Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The study investigates the efficacy and safety of dupilumab in the treatment of keloids
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborator:
Regeneron Pharmaceuticals